Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
Translating Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,510,085.00
Summary
Breast cancer is the most common cancer in women. Despite improvements in prevention, detection and treatment, it is the 2nd most common cause of cancer death in Australian women. Research advances in the last decade have improved our understanding of the pathways from susceptibility to progression and metastasis but this has mostly not yet translated into better outcomes. This program aims to translate some of our fundamental discoveries to improve outcome for affected women and their families.
Cellular And Molecular Aspects Of Mammographic Density As A Predictor Of Breast Cancer Risk In Pseudo-orthotopic Mammatrophic Environment
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
High mammographic density (MD), or denser breast tissue on mammogram, is associated with greater breast cancer risk. Despite this, the basis for its increased risk is poorly understood. This study assesses the effect of high density breast tissue transferred from high risk women at time of mastectomy into tissue engineering chambers in mice. Changes in the connective tissue harvested from the chamber were examined with specialized imaging, laboratory stains and molecular analysis.
KConFaB - A CONSORTIUM FOR RESEARCH ON FAMILIAL BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$1,624,711.00
Summary
Breast cancer is the most common disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australia-wide study is to collect clinical, epidemiological and genetic data on approximately 700 of these severely-affected families. This national resource will be of great value for researchers who want to identify and characterize the genetic and life-style factors that affect the onset and progression of t ....Breast cancer is the most common disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australia-wide study is to collect clinical, epidemiological and genetic data on approximately 700 of these severely-affected families. This national resource will be of great value for researchers who want to identify and characterize the genetic and life-style factors that affect the onset and progression of the disease. The data emerging from the study will lead to more accurate genetic counselling, better surveillance and, ultimately, better methods to prevent and treat the disease in families who inherit a predisposition to the disease.Read moreRead less
CLINICAL CHARACTERIZATION OF GENETICALLY DEFINED GERMLINE SUB-GROUPS OF MELANOMA AND BREAST CANCER PATIENTS.
Funder
National Health and Medical Research Council
Funding Amount
$140,949.00
Summary
In this project I will assess how cancer patients’ genetic makeup influences the nature and outcome of their cancer, especially in terms of how successful treatment is likely to be. We will show how key genetic variants influence cancer behaviour and by combining these genes we will have a better understanding of how to develop more successful treatments.
Incidence And Prognosis Of Metastatic Breast Cancer: A Population-based Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$97,700.00
Summary
This project will provide the first Australian population-based estimates of metastaticbreast cancer (MBC) incidence and survival in women with an initial diagnosis of early stage cancer that reflect current treatment practices. This evidence will help: women with MBC and their clinicians to make decisions about treatment and plan supportive care; researchers planning trials of MBC therapies, and future planning of cancer services.
Incorporating Genomics Into Breast Cancer Management
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
This study will investigate use of genomic sequencing in advanced and early breast cancer. We will characterise genetic characteristics of patients who benefit from two different therapies in the metastatic setting. We will use circulating tumour DNA analysis to monitor for and genetically characterise minimal residual disease (MRD) in patients apparently cured by initial therapy. This will thus identify potential therapeutic targets for preventing MRD progressing to metastatic disease.
A Novel Role For CBF? As A Regulator Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$682,415.00
Summary
Whole genome sequencing studies of human breast tumours identified a handful of common significantly mutated genes, all previously linked to breast cancer, except one, CBF?. Preliminary data from our lab now show that CBF? may be a new regulator of human breast cancer and metastasis. Using mice with altered CBF? levels, breast cancer models and human patient cohorts, this study aims to identify a novel role for CBF? as a new regulator of human breast cancer and potential therapeutic target.
Breast And Ovarian Cancer: Beyond Genome Wide Association Studies
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
My research is focused on using genetic approaches to understand the basis of cancer, particularly breast and ovarian cancer. Although many risk factors have been identified for these cancers, they do not lend themselves to primary prevention, except for high risk individuals who opt for prophylactic surgery, and so there is an urgent need to understand the aetiology of these cancers in order to develop better risk prediction algorithms and risk reduction medications.